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Tiffany Branson RN, MSN
Otterbein University, Westerville, Ohio
What is Hypertrophic
obstructive
cardiomyopathy?
Hypertrophic obstructive
cardiomyopathy or HOCM, is a genetic
disease that is described as hypertrophy
or enlargement of the left ventricle
which obstructs the blood flow to the
body (Yue-Cheng et al., 2012). HOCM is
a disease that cannot be cure, but can be
treated. One of the main goals of
treatment is to focus on treating the
symptoms. HOCM can be asymptomatic
or symptomatic and can cause some
major complications. Some of the
complications of HOCM are arrhythmias
and sudden cardiac death, “which is
defined as natural death to due cardiac
causes, heralded by abrupt loss of
consciousness within one hour of the
onset of acute symptoms” (Spiritio et al,
2009, p. 1704).

(Lookfordiagnosis.com, 2014)

(Lookfordiagnosis.com, 2014)

Signs and Symptoms
Patients with HOCM can range from
having no symptoms at all,
asymptomatic, to being very
symptomatic becoming restricted.
Some of the common symptoms of
HOCM are:
•

Shortness of breath. “Most of the
time shortness of breath
correlates to the heart not being
able to increase cardiac output
upon excretion (Whitten, 2008,
p. 47-48).

•

Chest pain. Decrease profusion
in the microcoronary circulation
plays a role in the cause of chest
pain (Whitten, 2008, p. 47-48). .

•

Syncope. Syncope occurs from
decreased cerebral perfusion
(Whitten, 2008, p. 47-48). .

•

Arrhythmias. Patients with
HOCM will sometimes have
arrhythmias due to ventricular
remolding, decrease cardiac
output, microcoronary ischemia,
and hypotension. “The most
common types of arrhythmias
seen with HOCM patients are
Atrial Fibrillation (A fib), Atrial
Flutter (A flutter),
supraventricular tachycardia
(SVT), ventricular tachycardia
(VT), and heart blocks (Whitten,
2008, p. 47-48).

•

Pathophysiology and Diagnosis of HOCM
Hearing a systolic murmur or holding
“HOCM is an autosomal dominant
an electrocardiograph (ECG) that looks
disease characterized by left ventricular
abnormal could possible indicate that
(LV) hypertrophy and left ventricular
the patient has HOCM. Confirmation of
outflow tract obstruction” (Yue-Cheng et
HOCM is made with an
al., 2012, p. 86) in the absence of an
echocardiography. The
underlying condition causing hypertrophy echocardiography shows LV
(Ommen, 2011). In HOCM the myocardial hypertrophy. Once the diagnosis of
sarcomere proteins result in muscle
HOCM is made screening should be
disarray and fibrosis, ultimately causing
done for the immediate family for the
inappropriate left ventricular hypertrophy autosomal dominant disorder
(Ommen, 2011). This abnormal gene is
(Nishimura & Holmes, 2004).
causing the muscle of the heart to thicken
The wall dividing the right and left
“HOCM is an autosomal dominant
ventricle becomes thick and gets in the
mutation of genes” (Gersh et al, 2011 p.
way or obstructs the flow of the blood to
2710) and genetic testing is done to
the rest of the body. (Hypertrophic
identify any relatives that may be
Cardiomyopathy, 2014). Because of the
affected with this disorder. Genetic
hypertrophy LV during the systolic period testing is used to determine which firstthe hypertrophic interventricular septum
degree family members are at risk for
protrudes into the left ventricular outflow developing HOCM (Gersh et al, 2011).
tract (LVOT) and the anterior mitral valve Genetic counseling can be done prior to
leaflet moves forward, causing the LVOT to the testing and will help the family
become narrowed or obstructed (Yuemembers better understand the
Cheng et al, 2012 p. 88). The obstruction
reasoning for the test, risk and benefits
decreases coronary perfusion pressure
for taking the test, and can help the
and causes decreased in cardiac output
response of learning that an individual
(Whitten, 2008,).
in the family does have a mutation of
the gene (Gersh et al, 2011).

Medical Therapy
Treatment is done to relive the
symptoms. In HOCM the goal is to
improve the signs and symptoms by
“decreasing the heart rate, decreasing
outflow obstruction, decreasing the
oxygen demand, improving the LV
relaxation, and improve filling
parameters and preventing major
complications” (Whittwen, 2008, p49).
Initially the first medication used will be
a beta-blocker to help slow the heart rate
to enhance diastolic filling (Nishimura &
Holmes, 2004). If the patient cannot
tolerate beta-blockers, a calcium channel
blocker like Verapamil will be used to
help improve the symptoms of HOCM
(Nishimura & Holmes, 2004), and
Verapamil can also improve the function
of the LV (Hamada, Ikeda, & Shigematsu,
2014). “Beat-blockers are effective in
relieving clinical symptoms, and calcium
antagonists, such as Verapamil, are
effective in attenuating LV diastolic
dysfunction” (Hamada, Ikeda, &
Shigematsu, 2014, p. 3). Antiarrhythmic
medications such as Amiodarone, can be
used in HOCM patients who have
developed arrhythmias like A fib (Maron
& Maron, 2013).

Surgical Treatment

Conclusion

When pharmacological treatment is
not enough, other options need to be
considered. Two invasive procedures,
surgical myectomy and percutaneous
transluminal septal myocardial ablation
(PTSMA), can be done to patients where
medication is not working. “Surgical
myectomy involves excision of a
rectangular part of the thickened
subaortic septum. Surgical myectomy
ameliorates signs and symptoms in about
70% of patients” (Whitten, 2008, p. 50).
PTSMA was introduced in 1995 as an
alternative to myectomy and has been
shown to reduce the LVOT obstruction
and associated symptoms” (Jensen et at,
2011 p256). “PTSMA involves injecting
ethanol into one or more the septal
perforator arteries, producing a
controlled infarction of the myocardial
septum. A successful PTSMA results in
septal thinning with reduction in the
LVOT obstruction” (Whitten, 2008, p.
50). Between the two procedures
surgical myectomy is the treatment of
choice with HOCM patients. PTSMA is
recommended for older patients or
patients that absolutely do not want to
have surgery (Maron & Maron, 2013).

HOCM is a disease that will require
lifetime treatment and management.
HOCM can be defined as thickening of the
left ventricle with obstruction of blood
flow. Chest pain, syncope, and shortness
of breath are common symptom to see in
patients with HOCM. HOMC can be
treated with medications and surgical
procedures for advances cases where
medications no longer work. “Nurses
play a role in the knowledge of HOCM
and how to detect problems early on”
(Whitten, 2008 p. 52)

Implications for
Nurses
“Nurses need to understand the
pathophysiology, management, features,
and complications of HOCM” (Whitten,
2008, p. 50). Nurses should talk with the
patient regarding their medications and
why they are on them. Nurses should
also be aware of what HOCM is and the
symptoms of it and what some of the
major complications of HOCM are. When
patients arrive to units post procedure,
nurses should be monitoring vital signs,
assessing the access site for signs and
symptoms of bleeding, swelling,
firmness and infection.

The most drastic symptom of
HOCM is sudden cardiac death
(SCD), which is common in
young patients and previously
asymptomatic patients (Prinz,
Farr, Hering, Horstkotte, &
Faber, 2011).”

(South Carolina Heart Center, 2014)
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